These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Simvastatin and pravastatin equally improve flow-mediated dilation in males with hypercholesterolemia. Sebestjen M, Boh M, Keber I. Wien Klin Wochenschr; 2002 Dec 30; 114(23-24):999-1003. PubMed ID: 12635468 [Abstract] [Full Text] [Related]
5. Comparison of the antiatherosclerotic effects of dihydropyridine calcium channel blocker and HMG-CoA reductase inhibitor on hypercholesterolemic rabbits. Takayama M, Matsubara M, Arakawa E, Takada C, Ina Y, Hasegawa K, Yao K. Vascul Pharmacol; 2007 Apr 30; 46(4):302-8. PubMed ID: 17197250 [Abstract] [Full Text] [Related]
8. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences. Lennernäs H, Fager G. Clin Pharmacokinet; 1997 May 30; 32(5):403-25. PubMed ID: 9160173 [Abstract] [Full Text] [Related]
13. Differential effect of LFA703, pravastatin, and fluvastatin on production of IL-18 and expression of ICAM-1 and CD40 in human monocytes. Takahashi HK, Mori S, Iwagaki H, Yoshino T, Tanaka N, Weitz-Schmidt G, Nishibori M. J Leukoc Biol; 2005 Mar 30; 77(3):400-7. PubMed ID: 15618295 [Abstract] [Full Text] [Related]